HR-1796 : Still Just a Bill

The Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025 (H.R. 1796) aims to improve the prevention and treatment of sickle cell disease and other heritable blood disorders.

Key provisions of the bill include:

• Reauthorizing and expanding a sickle cell disease prevention and treatment demonstration program.
• Modifying the program to focus on both the treatment of sickle cell disease and the prevention and treatment of complications arising from the disease.
• Expanding the types of entities that can participate in the program by allowing grants, contracts, or cooperative agreements.
• Increasing funding for the program to $8,205,000 per fiscal year from 2025 through 2029. Previously, it was $4,455,000 for each of fiscal years 2019 through 2023.
• Expressing the sense of Congress that further research is needed to understand the causes and find cures for heritable blood disorders, including sickle cell disease.

In short, this bill reauthorizes and expands an existing program, increases its funding, and broadens its scope to better address the treatment and prevention of complications related to sickle cell disease.